Combating Counterfeit Pharmaceuticals Act of 2025
Sen. Cotton Introduces Bill to Expand Sanctions on Foreign Counterfeit Drug Traffickers
This bill is currently in the early stages of the legislative process after being sent to the Senate Committee on Banking, Housing, and Urban Affairs for review. It is considered active, but no further hearings or votes have been scheduled at this time.
Legislative Progress
While drug safety is a popular topic, the bill was just introduced and currently lacks the bipartisan support needed to move quickly through the Senate.
Key Points
Impact Analysis
Personal Impact
Programs
Medicaid recipients who may be more vulnerable to encountering counterfeit drugs (due to cost pressures or supply chain issues) could benefit from stronger enforcement against fake medications. By expanding the government's ability to sanction foreign counterfeit drug traffickers, the bill aims to reduce the number of dangerous imitation drugs that reach consumers.
Disabilities
Milestones
Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
News
No related news coverage found for this legislation yet.
Source Information
Document Type
Congressional Bill
Official Title
Combating Counterfeit Pharmaceuticals Act of 2025
Data Sources
Sponsor
Cosponsors
(1)Analysis generated by AI. Always verify with official sources.